These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 30516105)

  • 21. Structure-based discovery and optimization of potential cancer therapeutics targeting the cell cycle.
    Thomas MP; McInnes C
    IDrugs; 2006 Apr; 9(4):273-8. PubMed ID: 16596481
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The design of novel inhibitors for treating cancer by targeting CDC25B through disruption of CDC25B-CDK2/Cyclin A interaction using computational approaches.
    Li HL; Ma Y; Ma Y; Li Y; Chen XB; Dong WL; Wang RL
    Oncotarget; 2017 May; 8(20):33225-33240. PubMed ID: 28402259
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An analysis of the binding modes of ATP-competitive CDK2 inhibitors as revealed by X-ray structures of protein-inhibitor complexes.
    Vulpetti A; Pevarello P
    Curr Med Chem Anticancer Agents; 2005 Sep; 5(5):561-73. PubMed ID: 16178778
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Insights on Structural Characteristics and Ligand Binding Mechanisms of CDK2.
    Li Y; Zhang J; Gao W; Zhang L; Pan Y; Zhang S; Wang Y
    Int J Mol Sci; 2015 Apr; 16(5):9314-40. PubMed ID: 25918937
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure-based drug design to the discovery of new 2-aminothiazole CDK2 inhibitors.
    Vulpetti A; Casale E; Roletto F; Amici R; Villa M; Pevarello P
    J Mol Graph Model; 2006 Mar; 24(5):341-8. PubMed ID: 16260160
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design, synthesis and biological evaluation of pyrimidine derivatives as novel CDK2 inhibitors that induce apoptosis and cell cycle arrest in breast cancer cells.
    Wang Y; Chen Y; Cheng X; Zhang K; Wang H; Liu B; Wang J
    Bioorg Med Chem; 2018 Jul; 26(12):3491-3501. PubMed ID: 29853338
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent advances on structure-informed drug discovery of cyclin-dependent kinase-2 inhibitors.
    Duca JS
    Future Med Chem; 2009 Nov; 1(8):1453-66. PubMed ID: 21426059
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduction of Cdc25A contributes to cyclin E1-Cdk2 inhibition at senescence in human mammary epithelial cells.
    Sandhu C; Donovan J; Bhattacharya N; Stampfer M; Worland P; Slingerland J
    Oncogene; 2000 Nov; 19(47):5314-23. PubMed ID: 11103932
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Benzothiophene inhibitors of MK2. Part 1: structure-activity relationships, assessments of selectivity and cellular potency.
    Anderson DR; Meyers MJ; Kurumbail RG; Caspers N; Poda GI; Long SA; Pierce BS; Mahoney MW; Mourey RJ
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4878-81. PubMed ID: 19616945
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advances in Pyrazole Based Scaffold as Cyclin-dependent Kinase 2 Inhibitors for the Treatment of Cancer.
    Shaikh J; Patel K; Khan T
    Mini Rev Med Chem; 2022; 22(8):1197-1215. PubMed ID: 34711160
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel binding pocket of cyclin-dependent kinase 2.
    Chen H; Van Duyne R; Zhang N; Kashanchi F; Zeng C
    Proteins; 2009 Jan; 74(1):122-32. PubMed ID: 18615713
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An integrated chemical biology approach provides insight into Cdk2 functional redundancy and inhibitor sensitivity.
    Echalier A; Cot E; Camasses A; Hodimont E; Hoh F; Jay P; Sheinerman F; Krasinska L; Fisher D
    Chem Biol; 2012 Aug; 19(8):1028-40. PubMed ID: 22921070
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of phosphorylated Thr160 for the activation of the CDK2/Cyclin A complex.
    De Vivo M; Cavalli A; Bottegoni G; Carloni P; Recanatini M
    Proteins; 2006 Jan; 62(1):89-98. PubMed ID: 16292742
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Theoretical studies on the selective mechanisms of GSK3β and CDK2 by molecular dynamics simulations and free energy calculations.
    Zhao S; Zhu J; Xu L; Jin J
    Chem Biol Drug Des; 2017 Jun; 89(6):846-855. PubMed ID: 27863047
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A subset of cancer cell lines is acutely sensitive to the Chk1 inhibitor MK-8776 as monotherapy due to CDK2 activation in S phase.
    Sakurikar N; Thompson R; Montano R; Eastman A
    Oncotarget; 2016 Jan; 7(2):1380-94. PubMed ID: 26595527
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Triazolo[1,5-a]pyrimidines as novel CDK2 inhibitors: protein structure-guided design and SAR.
    Richardson CM; Williamson DS; Parratt MJ; Borgognoni J; Cansfield AD; Dokurno P; Francis GL; Howes R; Moore JD; Murray JB; Robertson A; Surgenor AE; Torrance CJ
    Bioorg Med Chem Lett; 2006 Mar; 16(5):1353-7. PubMed ID: 16325401
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Searching for cyclin-dependent kinase inhibitors using a new variant of the cope elimination.
    Griffin RJ; Henderson A; Curtin NJ; Echalier A; Endicott JA; Hardcastle IR; Newell DR; Noble ME; Wang LZ; Golding BT
    J Am Chem Soc; 2006 May; 128(18):6012-3. PubMed ID: 16669651
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design, synthesis and biological study of novel pyrido[2,3-d]pyrimidine as anti-proliferative CDK2 inhibitors.
    Ibrahim DA; Ismail NS
    Eur J Med Chem; 2011 Dec; 46(12):5825-32. PubMed ID: 22000924
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structure-based approaches to improve selectivity: CDK2-GSK3beta binding site analysis.
    Vulpetti A; Crivori P; Cameron A; Bertrand J; Brasca MG; D'Alessio R; Pevarello P
    J Chem Inf Model; 2005; 45(5):1282-90. PubMed ID: 16180905
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular dynamics, density functional, ADMET predictions, virtual screening, and molecular interaction field studies for identification and evaluation of novel potential CDK2 inhibitors in cancer therapy.
    da Silva VB; Kawano DF; Gomes Ada S; Carvalho I; Taft CA; da Silva CH
    J Phys Chem A; 2008 Sep; 112(38):8902-10. PubMed ID: 18698751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.